Literature DB >> 30485563

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.

Rasmus Sørrig1,2, Tobias W Klausen3, Morten Salomo1, Annette Vangsted1,2, Peter Gimsing1.   

Abstract

OBJECTIVES: Infections pose the greatest risk of early death in patients with Multiple Myeloma. However, few studies have analyzed the risk factors for infections in Multiple Myeloma patients. The aim of this study was to analyze the risk factors infections within a population-based MM cohort.
METHODS: Using Danish registries (from 2005 to 2013), we analyzed all ICD-10 codes for infections within the first 6 months of Multiple Myeloma diagnosis in 2557 patients.
RESULTS: Pneumonia and sepsis represented 46% of infections. Multivariable regression analysis showed that risk factors for pneumonia were male gender (HR 1.4; P = 0.001), ISS II (HR 1.6; P = 0.0004) and ISSIII (HR 1.8; P = 0.0004) and elevated LDH (HR 2.6; P = 0.0008). Risk factors for sepsis were high bone marrow plasma cell % (HR 1.1; P = 0.038), ISS II (HR 1.7; P = 0.007) ISS III (HR 2.0; P = 0.002) and creatinine (HR 2.1; P = 0.002). Neither immunoparesis (hypogammaglobulinemia) nor comorbidity was significant risk factors.
CONCLUSIONS: Our study suggests that tumor burden and renal impairment are risk factors for pneumonia and sepsis in the early phase of Multiple Myeloma.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  immunoparesis; infection; multiple myeloma; risk factors

Mesh:

Substances:

Year:  2018        PMID: 30485563     DOI: 10.1111/ejh.13190

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  12 in total

1.  Mental foramen in panoramic radiography can be a reference for discrimination of punched-out lesions in the mandible in patients with symptomatic multiple myeloma: A cross-sectional study.

Authors:  Yasuyuki Shimada; Yuki Shiko; Fumihiko Nakamura; Akira Hangaishi; Yohei Kawasaki; Yutaka Maruoka
Journal:  Glob Health Med       Date:  2022-06-30

Review 2.  Facts and Hopes in Multiple Myeloma Immunotherapy.

Authors:  Adam S Sperling; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2021-03-26       Impact factor: 12.531

3.  Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center.

Authors:  Zi-Shan Lin; Xiao-Juan Yu; Xu Zhang; Su-Xia Wang; Xi-Nan Cen; Fu-De Zhou; Ming-Hui Zhao
Journal:  Cancer Manag Res       Date:  2021-05-13       Impact factor: 3.989

4.  A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.

Authors:  Taher Sabobeh; Emily K Brugioni; Amgad Masoud; Sheshadri Madhusudhana; Valerica Mateescu
Journal:  Cureus       Date:  2021-02-11

Review 5.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

Review 6.  Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).

Authors:  Evangelos Terpos; Monika Engelhardt; Gordon Cook; Francesca Gay; Maria-Victoria Mateos; Ioannis Ntanasis-Stathopoulos; Niels W C J van de Donk; Hervé Avet-Loiseau; Roman Hajek; Annette Juul Vangsted; Heinz Ludwig; Sonja Zweegman; Philippe Moreau; Hermann Einsele; Mario Boccadoro; Jesus San Miguel; Meletios A Dimopoulos; Pieter Sonneveld
Journal:  Leukemia       Date:  2020-05-22       Impact factor: 12.883

7.  Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.

Authors:  Ilaria J Chicca; Jennifer L J Heaney; Gulnaz Iqbal; Janet A Dunn; Stella Bowcock; Guy Pratt; Kwee L Yong; Timothy D Planche; Alex Richter; Mark T Drayson
Journal:  Blood Cancer J       Date:  2020-11-04       Impact factor: 11.037

Review 8.  Immunotherapeutic and Targeted Approaches in Multiple Myeloma.

Authors:  Omar Nadeem; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotargets Ther       Date:  2020-10-14

9.  Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.

Authors:  Chunmei Ye; Weiwei Chen; Qi Gao; Yanxia Chen; Xiaolu Song; Sujie Zheng; Jinlin Liu
Journal:  Med Sci Monit       Date:  2021-07-09

10.  Outcome of COVID-19 in multiple myeloma patients in relation to treatment.

Authors:  Katharina Helene Susek; Charlotte Gran; Hans-Gustaf Ljunggren; Evren Alici; Hareth Nahi
Journal:  Eur J Haematol       Date:  2020-08-18       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.